Predominant Single Stable VpmaV Expression in Strain GM139 and Major Differences with Mycoplasma agalactiae Type

Maysa Santos Barbosa1,2, Joachim Spergser1, Lucas Miranda Marques2,3

  • 1Institute of Microbiology, Department of Pathobiology, University of Veterinary Medicine, 1210 Vienna, Austria.

Insights

Mycoplasma agalactiae uses variable surface lipoproteins (Vpmas) for immune evasion. Strain GM139

Area of Science:

  • Microbiology
  • Immunology
  • Bacteriology

Background:

  • Mycoplasmas, including Mycoplasma agalactiae, possess mechanisms for antigenic variation in surface lipoproteins.
  • Variable proteins of M. agalactiae (Vpmas) are lipoproteins involved in immune evasion, colonization, dissemination, and persistence.
  • Vpmas undergo high-frequency phase variation, modulating host interactions.

Purpose of the Study:

  • To evaluate Vpma phenotypic profiles of Mycoplasma agalactiae strains GM139 and PG2.
  • To assess correlations between Vpma phase variability and strain pathogenicity, geographic origin, and animal source.
  • To understand the role of Vpma expression in differential pathogenicity.

Main Methods:

  • Immunoblot analysis using monospecific Vpma antibodies.
  • Phenotypic characterization of Vpma expression in different strains.
  • MALDI-ToF MS analysis for strain relatedness.

Main Results:

  • Mycoplasma agalactiae strain PG2 expresses six Vpma proteins with high-frequency phase variation.
  • Strain GM139 predominantly expresses VpmaV and lacks high-frequency Vpma phase variation.
  • MALDI-ToF MS revealed significant differences between GM139, PG2, and other M. agalactiae strains.

Conclusions:

  • Predominant expression of VpmaV without high-frequency variation in GM139 may explain its differential pathogenicity compared to PG2.
  • Vpma phase variation significantly impacts Mycoplasma agalactiae virulence and host interaction.
  • Distinct Vpma profiles contribute to the genetic diversity and pathogenicity of M. agalactiae strains.